Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study
- PMID: 23532105
- DOI: 10.1097/SLA.0b013e31828ee17c
Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study
Abstract
Objective: The purpose of this study was to assess outcomes and indications in a large cohort of patients who underwent liver transplantation (LT) for liver metastases (LM) from neuroendocrine tumors (NET) over a 27-year period.
Background: LT for NET remains controversial due to the absence of clear selection criteria and the scarcity and heterogeneity of reported cases.
Methods: This retrospective multicentric study included 213 patients who underwent LT for NET performed in 35 centers in 11 European countries between 1982 and 2009. One hundred seven patients underwent transplantation before 2000 and 106 after 2000. Mean age at the time of LT was 46 years. Half of the patients presented hormone secretion and 55% had hepatomegaly. Before LT, 83% of patients had undergone surgical treatment of the primary tumor and/or LM and 76% had received chemotherapy. The median interval between diagnosis of LM and LT was 25 months (range, 1-149 months). In addition to LT, 24 patients underwent major resection procedures and 30 patients underwent minor resection procedures.
Results: Three-month postoperative mortality was 10%. At 5 years after LT, overall survival (OS) was 52% and disease-free survival was 30%. At 5 years from diagnosis of LM, OS was 73%. Multivariate analysis identified 3 predictors of poor outcome, that is, major resection in addition to LT, poor tumor differentiation, and hepatomegaly. Since 2000, 5-year OS has increased to 59% in relation with fewer patients presenting poor prognostic factors. Multivariate analysis of the 106 cases treated since 2000 identified the following predictors of poor outcome: hepatomegaly, age more than 45 years, and any amount of resection concurrent with LT.
Conclusions: LT is an effective treatment of unresectable LM from NET. Patient selection based on the aforementioned predictors can achieve a 5-year OS between 60% and 80%. However, use of overly restrictive criteria may deny LT to some patients who could benefit. Optimal timing for LT in patients with stable versus progressive disease remains unclear.
Comment in
-
Liver transplantation for unresectable metastases to the liver: a new era in transplantation or a time for caution?Ann Surg. 2013 May;257(5):816-7. doi: 10.1097/SLA.0b013e3182908c8d. Ann Surg. 2013. PMID: 23532106 No abstract available.
-
[Liver transplantation as effective treatment for non-resectable liver metastases of neuroendocrine tumors].Chirurg. 2013 Jul;84(7):600. doi: 10.1007/s00104-013-2544-6. Chirurg. 2013. PMID: 23743994 German. No abstract available.
Similar articles
-
Liver transplantation for unresectable neuroendocrine tumor liver metastases.Ann Surg Oncol. 2014 Jul;21(7):2398-405. doi: 10.1245/s10434-014-3523-y. Epub 2014 Feb 22. Ann Surg Oncol. 2014. PMID: 24562931 Review.
-
The place of liver transplantation in the treatment of hepatic epitheloid hemangioendothelioma: report of the European liver transplant registry.Ann Surg. 2007 Dec;246(6):949-57; discussion 957. doi: 10.1097/SLA.0b013e31815c2a70. Ann Surg. 2007. PMID: 18043096
-
Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database.Arch Surg. 2011 Aug;146(8):953-8. doi: 10.1001/archsurg.2011.186. Arch Surg. 2011. PMID: 21844436
-
Liver transplantation and neuroendocrine tumors: lessons from a single centre experience and from the literature review.Transpl Int. 2010 Jul;23(7):668-78. doi: 10.1111/j.1432-2277.2010.01086.x. Epub 2010 May 5. Transpl Int. 2010. PMID: 20478000 Review.
-
Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy?Ann Surg. 2003 Oct;238(4):508-18; discussion 518-9. doi: 10.1097/01.sla.0000090449.87109.44. Ann Surg. 2003. PMID: 14530722 Free PMC article.
Cited by
-
Evolution of Liver Transplantation Indications: Expanding Horizons.Medicina (Kaunas). 2024 Feb 28;60(3):412. doi: 10.3390/medicina60030412. Medicina (Kaunas). 2024. PMID: 38541138 Free PMC article. Review.
-
Transplant oncology - Current indications and strategies to advance the field.JHEP Rep. 2023 Nov 16;6(2):100965. doi: 10.1016/j.jhepr.2023.100965. eCollection 2024 Feb. JHEP Rep. 2023. PMID: 38304238 Free PMC article. Review.
-
Metabolic Tumor Volume from 18F-FDG PET/CT in Combination with Radiologic Measurements to Predict Long-Term Survival Following Transplantation for Colorectal Liver Metastases.Cancers (Basel). 2023 Dec 19;16(1):19. doi: 10.3390/cancers16010019. Cancers (Basel). 2023. PMID: 38201449 Free PMC article.
-
Transplant Oncology: An Emerging Discipline of Cancer Treatment.Cancers (Basel). 2023 Nov 9;15(22):5337. doi: 10.3390/cancers15225337. Cancers (Basel). 2023. PMID: 38001597 Free PMC article. Review.
-
Predictors of Long-Term Outcomes After Liver Transplantation for Unresectable Metastatic Neuroendocrine Tumors.Ann Transplant. 2023 Nov 21;28:e941212. doi: 10.12659/AOT.941212. Ann Transplant. 2023. PMID: 37986542 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical